Wells Fargo raised the firm’s price target on Natera (NTRA) to $205 from $190 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $270 from $230 at Barclays
- Natera, Medica Scientia Innovation Research to collaborate on MiRaDoR study
- Natera announces initial translational research data from Phase 3 study
- Natera files to sell 1.95M shares of common stock for holders
- Natera Acquires Foresight Diagnostics for $275 Million